Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL! 5-6 hours a night.
I can see how that came off as rude; my apologies. I want everyone to make money, and since 400% on 700,000 shares is really good money (compare it to the interest you can make in a bank savings account or a cd), I thought it would be helpful for him to hear another perspective. Selling at 400% profit is nothing to be ashamed of. Again, sorry for coming off as rude.
Impressive! I'd love to get ahold of your algorithms. That's a lot of trades per day!
What you say is well taken; I'm not a chart/technical guru, so I have to go off of company fundamentals and investor sentiment (MOMO). I'd rather have your gifts and talents; my life would be much easier!
No; I'm not saying 80,000 is impressive. I'm saying that selling too early can work, and that making 5% on a bunch of stocks adds up to a lot after a while, rather than trying to make 1000% on one stock. Anyone who has been trading for a while knows the sick feeling of being a bag-holder, and no one ultimately knows what the share price will do. If we knew for sure it would go up, we'd all buy more shares and no one would short it. Locking in 400-500% profits is awesome! Next week it may be gone, or it may be doubled.
I've made $80,000 in the past 12 months by selling too early. To each his own. GLTA.
400%??!! My advice...SELL. Lock in your profits. This stock is a pinky; the chances of it going anywhere after the MOMO leaves are very slim. Don't be a bag holder!
For those of you who are selling, hold your shares for a while; you'll be able to sell them, if you wish, at .017 instead of at .012
A couple million share bids and we'll be at a new high of day.
Hold your shares tight; make them come up to .013 and .014 to buy them! People are buying!
Hold your shares, folks, you'll be rewarded for doing so. It looks like .013 is soon to come on the next leg up if we stop selling for a couple hours.
Closing near high of day; get ready for a fairly substantial gap up again tomorrow!
Take profits! This is a penny stock running on MOMO; don't get caught holding the bag.
Oops; meant to say there will be some selling in mass and some buying in mass. LOL...nevermind. This board is better off ignoring me state the obvious!
Hope everyone has their shares for next week; if history repeats itself it should be a volatile week: some exiting in mass and some selling in mass. Have a great weekend; see you Monday.
Valid point
I couldn't agree more, except that BBDA has an actual product selling all over the U.S. and with plans, soon to be announced, of spreading into Europe and Asia. If this company was a scam with no real product (like a majority of the mining companies are), then I'd say differently.
Thanks fidcow; You are probably right, but I have been receiving quite a bit of due diligence from this board and from Vringo Free Forum (I've seldom been on Yahoo) to keep informed enough to invest. If there comes a time when fellow longs are no longer able to provide intelligent commentary on articles written against VRNG, then I'll be forced to sell because I am not well-versed enough in patent litigation to navigate these waters on my own. What you said is well taken.
Yes; and the frustrating part is I don't know enough to be able to tell if the argumentation he uses is valid, and if the precedent is relevant to Vringo. I'd love to see VRNG go North; if it does I'll be making a ton of money like the majority of us here. But I also don't want to invest with blinders on. The question I am always trying to answer is, "Is it true?" Because if something is true, then I need to act on it.
New Seeking Alpha article; makes me want to liquidate my entire position in VRNG before it drops through the floor. Does anyone have an intelligent commentary on the article?
Ravicher Splitting Vringo's Genes Behind The Scenes?
February 7, 2013 | 6 comments | about: VRNG, includes: GOOG
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Background
Vringo (VRNG) is suing Google (GOOG) (and some other companies too (MSFT)) for search engine patents. None of the cases have reached appeal yet. Although nobody has bothered to write much about it in Vringo's context, Mayo is a Supreme Court precedent signaling that Vringo will lose on appeal. I have written about it in prior articles, so I will simply repeat this for the introduction, and then we can move on to the new Supreme Court case, which is AMP.
The Real Issue: Abstract Ideas and Laws of Nature
Bitlaw has a summary of the only recent Supreme Court decision [Mayo] relating to software patent law. It was an unanimous decision. Quoting:
The claims of this patent essentially required three separate steps: administering a drug to a patient, measuring a metabolite created by the body of the patient as a result of the drug, and informing whether more or less drug should be administered to the patient based on the measured levels of the metabolite. In this invention, the drug was known in the prior art, as was the fact that the drug produced the metabolite. Even the fact that the metabolite levels could be used to determine the efficacy of the dosage of the drug was previously known. What was not known was the precise correlations between the metabolite levels and the efficacy of the drug.
Vringo's patent is like this drug test. Search user scores are a test, measuring the rank of a link. These ranks, like the metabolite levels, are established through correlation. There are a variety of statistical approaches for establishing the precise correlations, and the fact that correlations exist between link quality and user identity was already known. These precise correlations, and various routes to implementation, like intricacies of the drug test, are not patentable.
Overlapping Cases
Mayo has provided a Supreme Court precedent overthrowing broad, abstract diagnostic processes. But, lower courts so far have been interpreting this precedent inconsistently. Lower courts often ignore the Supreme Court for patents when allowed to. But there are limits to such disobedience. Repeat precedents are not ignorable.
The pending Supreme Court case, AMP, tests the patentability of genetically dynamic cell diagnostics. It could help bridge Mayo's application to Vringo. Methods for ordering search signals are like methods for sequencing DNA signals. The process: isolating anomalies from their natural states, applying the extracted information, and updating the model. Patent law expert Dan Ravicher is among those litigating to destroy such patentability in AMP.
Ravicher's PUBPAT and ACLU write on page 56 (edited for formatting):
These claims give rise to the same concern expressed by this Court in Mayo regarding how patents "threaten to inhibit the development of more refined treatment recommendations." The "isolated" DNA claims allow Myriad to dictate the standard of testing that is offered. It is undisputed that for several years, Myriad was performing tests that did not identify all known mutations. Women with mutations not detected by Myriad's tests were and continue to be given falsely reassuring results.
Indeed, Myriad continues to separate testing for large genetic rearrangements from its standard testing, even though national guidelines recommend that patients receive such testing. Moreover, Myriad's monopoly on the BRCA genes prevents other laboratories from including these genes when clinically assaying the over twenty genes now known to be associated with hereditary risk for breast and ovarian cancer or when using next generation testing methods.
Ravicher and friends weave a very relevant narrative in this gene case AMP. Myriad was granted a monopoly to perform tests. Myriad was performing tests, but not enough of them. When important technologies are restricted by patent monopolies, we risk important applications being neglected.
If we were to go back to when Vringo's patents were originally filed, respect the monopoly implied by the filing, and restrict Google from innovating, who knows how much progress we would have missed out on as a society? Technological uncertainty is antifragile: we simply cannot predict who the next Google is -- so we must not set system-wide precedents such as Vringo's.
Every lawyer knows: the higher up one goes in appeals, the harder it is to prosecute patents.
USPTO and trial court is a proletariat retail broker happily collecting tolls from trolls; appeal court is a petty-bourgeois status arbiter, which like academia functions through groupthink; Supreme Court is the ruling class, or true bourgeois. This is the crass but accurate ROV framework for appeals hierarchy as the Supreme Court repeats Mayo with AMP.
The Supreme Court will reiterate its unanimous 9-0 stance as taken in Mayo. This will send a clear message to appeals court, where Vringo v. Google is inevitably headed. The message is: we ruled twice on this, so don't try to get cute helping out patent trolls - once could be a mistake, but twice is a commitment.
Sometimes the petty bourgeois need to be put in their place (if only to prop up their superiors). Here is what the lower appeals court said when it rejected Ravicher's gene team, ruling incorrectly against gene patent liberty with AMP. This is the idea which will be overturned:
isolated DNA which does not exist alone in nature can be patented [and the] drug screening claims were valid.
This is a subject-matter-patentability issue. In other words, the following principles will be simultaneously discharged by the Supreme Court:
the entire abstract set of all isolated search results (which do not exist alone in nature) can be patented.
Vringo's broad, abstract, fundamental screening claims (which describe all of Vringo's claims) were valid.
Vringo has a telecom trolling case in Germany, which I am quite pessimistic on for too many reasons to discuss here. The Google thing is not looking so good. I think Vringo stock should trade closer to $2 at this time, and frankly I think it probably goes to zero before it goes to $4.
Additional disclosure: The disclosures made are minimal and readers should assume writers have conflicts of some sort.
This article was sent to 5,733 people who get email alerts on VRNG.
I sold half my position on this run because one of my buy orders filled when AIG dumped their shares the other day. I've reverted to the strategy of many wiser than I: hold a core position in case she pops to the moon, and use other monies to buy low and sell high. So far this has worked well for me. I've recouped $5000 of the $12,000 I lost when I first bought in at the low 5's.
But, in case someone rages against me for being short, I am long. I don't know how to short stocks, nor do I have any desire to short stocks.
Hope this helps.
Yes it does. If history has anything to do with the future, the share price will be back down to $3.15 by tomorrow or soon after the "rumor effect" wears off. Now is a great to sell for a quick profit; you'll likely be able to buy back in much cheaper in a couple days.
According to Cliff at Investor Relations, ZTE denied any infringement (which is what VRNG thought they would do), so the 3 lawsuits filed against ZTE are going to court. Cliff said the investors will be updated via PR when the court dates are scheduled.
Vringo's Suit Against Microsoft - What The Past Tells Us
February 3, 2013 | 6 comments | about: MSFT, VRNG
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Intellectual property company Vringo (VRNG) is, through its subsidiary I/P Engine, suing Microsoft (MSFT) allegedly for infringement on two of its patents: U.S. Patent Nos. 6,314,420 and 6,775,664, entitled "Collaborative/Adaptive Search Engine" and "Information Filter System and Method for Integrated Content-Based and Collaborative/Adaptive Feedback Queries," respectively. The patents relate to the foundation framework for functioning of search engines.
Vringo says that Microsoft has and continues to infringe on the patents, and is seeking an award against Microsoft's "past and future compensatory damages amounting to no less than reasonable royalties, prejudgment interest and any other damages based on any form of recoverable economic injury." Such suits are sometimes initiated with the purpose of forcing defendants to make a settlement. Is this also one of them? I wrote extensively about Vringo and Google in the last months of 2012, and now I wish to follow up with those articles to see what we can understand about the present lawsuit.
Vringo: A Quick Recap
Formed in 2006, Vringo is a developmental-stage company. It is in the business of developing and monetization software for mobile phones and intellectual property. It provides a platform that allows consumers to create, download, and share mobile entertainment content in the form of ringtones.
Last year, the company merged with an intellectual property firm I/P Engine, which is in the business of licensing patents. In July 2012, Nokia (NOK) sold 500 patents and applications for pending patents to Vringo, which sold 9.6 million shares for $31.2 million in August 2012 to fund the purchase. The patents involved in the lawsuit with Microsoft were originally created by Lycos, an Internet search company.
This is not the first time Vringo is suing a tech giant. It has earlier taken on Google (GOOG), AOL (AOL), and three other companies. Vringo went global in its fight to enforce intellectual rights and filed a lawsuit in the U.K. High Court of Justice against ZTE Electronics (ZTE), a Chinese telecommunications equipment company that is also an OEM for other retail brands and the world's fifth largest in the telecommunications equipment industry. Microsoft is its latest target. Microsoft, incidentally, partners with Nokia in the smartphone space.
The Earlier Lawsuit
The jury validated infringement of patents and awarded damages based on running royalty, which meant that Vringo did not get what it was fighting for. While it got what it wanted for future royalty, it got only $30 million in past damages. The total sum awarded, $30 million, was bifurcated between the five respondents as follows:
Google: $15,800,000
AOL: $7,943,000
IAC: $6,650,000
Gannett: $4,322
Target: $98,833
Vringo has chosen to raise revenues by focusing on enforcing intellectual property rights. In the process, once it started taking tech behemoths to court over intellectual property rights, the company caught the attention of investors who support reforms in U.S. patent laws -- including Mark Cuban, who became a major shareholder in Vringo.
The company's shares have been reacting to news. When Google's application for a summary judgment was rejected, the stock went up 35% in one week. VRNG shares lost 8% in late-afternoon trading the day the judgment was announced and it became clear that Vringo was awarded only $30 million in past damages instead of the amount it wanted. On the announcement of Vringo's lawsuit against ZTE Corp., the company's shares went up 17%.
Summary
As I said earlier, such lawsuits are often filed in order to push the defendant to reach an out-of-court settlement. In the earlier lawsuit, Google went all out to fight the claim, while AOL came to a partial settlement of $100,000 for the patents it was using for "in-house products, but not for [its] use of Google's products." It now depends largely on Microsoft whether it is going to fight the case, or try for a settlement out of court. The charge is that Microsoft is infringing on the same patents through its search engine, Bing.
This is a big if, but if I am correct in my assumption then Vringo can hope only for running royalty (calculated at 3.5% in the previous judgment), and forget about past damages. However, it would not be a bad idea to invest in Vringo as a hedging strategy just as Mark Cuban's investment in the company was a strategy for hedging against his investments in companies that are exposed to patent infringement.
This article was sent to 5,676 people who get email alerts on VRNG.
Happy weekend all. Hopefully we hear some more good news about lawsuits etc. before Monday morning. See you then.
Well, it looks like we're at the commencement of what I'll call "bear week" next week. Shorts doing the best they can to drive the price down prior to the week of February 15. I am neither a prophet nor the son of a prophet, but if I had to guess, and "Yes", that is all this is, I'd guess next week will be more bearish than bullish (though I hope it isn't; I hope I'm wrong!) and that the week of February 15th will be more bullish. Just wanted to mention this in case any are wondering why a downward spike may have been occurring.
Notice the comments about cash. This company is not even close to filing for bankruptcy.
UPDATE: Celsion Shares Plunge on Drug's Trial Failure
2 minutes ago - Dow Jones News
(Adds details, company and analyst comment, and updated stock price.)
--Late-stage trial failure calls into doubt Celsion Corp.'s cancer drug technology
--Shares plunge more than 80% after tripling in last year
--Company says the study results were 'not close' to achieving trial's goal
By Joseph Walker
Celsion Corp. (CLSN) said its experimental drug technology failed to significantly slow the progression of liver cancer, failing to meet its primary goal, in a late-stage trial.
The failure called into doubt the near-term viability of Celsion's cancer drug, ThermoDox, which is also being studied in two mid-stage trials.
Shares plunged 81% to $1.52. Through Wednesday's close, shares had more than tripled over the past year to $8.38.
Celsion didn't release data from the trial but suggested the drug missed its goal by a wide margin. The trial sought to achieve a significant extension in the time that liver-cancer patients' survived without their diseases advancing.
"It was not close," Chief Executive Michael Tardugno said. "There was a modest improvement."
The Lawrenceville, N.J., biotechnology company said it will undertake a strategic review to assess the future of ThermoDox. It said it has about $27 million in cash and investments, which will carry it through this year and "well into 2014."
The company said it will consider following the currently enrolled patients to evaluate the secondary endpoint of overall survival.
ThermoDox is a form of the chemotherapy liposomal doxorubicin which, when activated by heat, delivers therapy directly to tumors.
"We know the mechanism of action is reliable," Mr. Tardugno said of the technology. "Whether or not that is of clinical value, we have a little more work to do."
The trial, known as the HEAT study, compared the use of ThermoDox in combination with radiation treatment versus radiation alone in liver-cancer patients.
Celsion said a mid-stage study of ThermoDox in breast cancer would continue to enroll patients. However, a mid-stage study in colon cancer that has spread to the liver would have to be re-evaluated after the failure disclosed Thursday.
"Given that the HEAT trial result was unimpressive enough to keep private, we can no longer have any confidence in other trial results," said Jonathan Aschoff, an analyst at Brean Capital LLC.
The study failure will make enrolling patients in subsequent trials difficult, Mr. Aschoff said, and "even if enrolled, a similar outcome will occur in future trials."
Gondy, I agree this thing will go up eventually as it is a legitimate company with plenty of cash, but your "pumping" comments are not helping things. Lay low; the stock will do what it will do.
Show the link to prove this, otherwise please cease throwing out unwarranted comments. This stock doesn't need any more manipulation or any other reason to go further South. For the sake of those who lost a lot of money, ease up.
When the selling pressure lets up, this thing should head North a little. We've traded about 27 million so far; there are only so many more shares to be sold and then it will have to let up a little.
Check out the latest PR. Like I said, I'm buying more. If you can read between the lines the VRNG team is doing a lot! Cliff can only say so much, but the fact of the matter is this stock is going places. GLTA.
Yes, it was a very respectable call.
Regarding scarcity of news as of late, he said:
We would love to release a PR every week, but unfortunately we cannot because we are in litigation right now. Many companies have run themselves into deep trouble by promoting themselves while in litigation. We are trying to be very careful about what we say and don't say.
Regarding the three lawsuits they have filed against ZTE, he said:
Things are in progress. ZTE responded claiming they are "not guilty" of infringement, so there will be three court dates, one for each lawsuit, scheduled for some time this year. The moment the court dates are set, they will release that news. In the German courts you have 3 hours before the judge, that is all. They handle things very quickly.
My take overall? (JMHO) These VRNG guys are level-headed and calculated, and they have in mind the long-term best for the shareholders. They have to be tight-lipped for the sake of not saying something which could get them into trouble later on. These guys are wise, not foolish, and they're not going to sacrifice, according to Cliff, the long-term monetary profitability of the company on the altar of short-term traders. Things will happen when they happen; VRNG will inform us when they happen. This is good news. I am greatly encouraged, and will not only hold my position strongly, but also add more in 3 days. Money's transferring.
I just checked my calendar and didn't realize February 15 is so close (mental block on my part). Two weeks from tomorrow night the documents will be in and the judge will thereafter thump the gavel. Including today, then, only 11 more trading days.
Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer
10 minutes ago - PR Newswire via Comtex
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.
Specifically, Celsion has determined, after conferring with its independent Data Monitoring Committee (DMC) that the HEAT Study did not meet the goal of demonstrating persuasive evidence of clinical effectiveness that could form the basis for regulatory approval in the population chosen for study. The HEAT Study was designed to show a 33% improvement in PFS with 80% power and a p-value = 0.05. In the trial, ThermoDox® was well-tolerated with no unexpected serious adverse events. The HEAT Study was conducted under a Special Protocol Assessment agreed to with the U.S. Food and Drug Administration (FDA).
"We are disappointed that the HEAT Study did not provide sufficient evidence of clinical effectiveness of ThermoDox® as measured by the trial's primary endpoint," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We will consider following the patients currently enrolled in the HEAT Study to the secondary endpoint, Overall Survival (OS), and are conducting additional analyses of the data from the trial in order to assess the future strategic value of ThermoDox. We expect that the results will be presented in the future at appropriate medical meetings. We wish to acknowledge and thank the patients and investigators who participated in the trial."
Celsion ended 2012 with a strong balance sheet that provides the Company the opportunity to evaluate its future development plans. The Company projects its unaudited cash and investment balance to be approximately $23 million as of December 31, 2012 and approximately $27 million as of January 31, 2013.
Conference Call
The Company is hosting a conference call to discuss the Phase III HEAT Study results at 8:00 a.m. EST today. To participate in the call, interested parties may dial 1-888-466-4462 (Toll-Free/North America) or 1-719-457-2627 (International/Toll) and ask for the Celsion Corporation Phase III HEAT Study Conference Call approximately 10 minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
The call will be archived for replay at 2 p.m. EST on January 31, 2013, and will remain available until February 14, 2013. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 4540212. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2p.m. EST on Thursday, January 31, 2013.
About the HEAT Study
HEAT (Hepatocellular Carcinoma Study of RFA and ThermoDox®) was an international, multi-center, randomized, placebo-controlled study that randomized 701 patients with intermediate (tumor size 3 cm to 7 cm), unresectable HCC to 50mg/m2 ThermoDox® plus RFA or RFA alone. The primary endpoint of the study was progression-free survival, as defined by the Special Protocol Assessment agreed to with the U.S. FDA. Safety and tolerability were also evaluated.
The HEAT Study, the largest clinical trial to date in patients with intermediate HCC, was conducted at 79 clinical sites around the world, including the United States, Canada, Italy, China, Taiwan, Hong Kong, Korea, Thailand, Malaysia and the Philippines.
About Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), also known as primary liver cancer, is currently one of the most common and deadly forms of cancer worldwide. With few approved treatment options, it is estimated that up to 90 percent of unresectable (inoperable) liver cancer patients will die within five years of diagnosis. HCC is the fourth leading cause of death from cancer and the third most common in males. There are approximately 26,000 new cases per year in the US and approximately 40,000 cases per year in Europe. However, HCC is rapidly growing worldwide at approximately 750,000 cases per year, due to the high prevalence of Hepatitis B and C in developing countries - more than 50 percent of these new cases will be in China. HCC currently is the world's fifth largest cancer and the World Health Organization estimates that HCC may become the number one cancer worldwide by 2020, surpassing lung cancer.
About ThermoDox®
ThermoDox® is an investigational, proprietary heat-activated formulation of liposomal doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers, and is currently being investigated in clinical trials for its potential to treat patients with intermediate (tumor size 3 to 7 cm), unresectable (inoperable) HCC. ThermoDox® is an investigational treatment and is not approved by the FDA, EMA or other health authorities.
ThermoDox® enhances the efficacy of doxorubicin by encapsulating it with Celsion's proprietary lysolipid thermally sensitive liposomes (LTSL). These heat-sensitive liposomes change structure when heated to a specific temperature (via a heat source like RFA), creating openings in the liposome that release doxorubicin directly into the targeted tumor and surrounding tissue. While the RFA targets the tumor, ThermoDox® delivers higher concentrations of chemotherapy directly to the tumor site, capturing micrometastases (tumors too miniscule to be detected) outside of the RFA ablation zone, which are most commonly responsible for post-treatment disease recurrence. In animal models, ThermoDox® has been shown to deliver 25 times more doxorubicin into tumors than intravenous doxorubicin, and five times more doxorubicin than standard liposomal formulations of the drug. Additionally, ThermoDox® is less permeable across normal blood vessels than free doxorubicin, minimizing systemic toxicity.
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs. The company is focused on advancing its heat-mediated, tumor-targeting drug delivery platform to address difficult-to-treat cancers. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the need for Celsion to analyze the results of the HEAT Study further; the need for Celsion to evaluate its future development plans; cash projections are unaudited; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
Investor ContactJeffrey W. ChurchSr. Vice President - Corporate Strategy and Investor Relations609-482-2455jchurch@celsion.com
Media ContactKimberly Ryan212-880-5289 kimberly.ryan@ogilvy.com
SOURCE Celsion Corporation
Well, we knew a bear run or two would take place, but most of us thought it would happen prior to January 25. Instead, it appears the bear run is going to happen prior to February 15, beginning already now. Hunker down; loading. There's good support so far.
Thanks CB!
Now that the massive 3.19 bid has been bought, do you mind posting another L2 screen shot?
If Vringo so much as sneezes anything which sounds like good news this thing is going to hit the sky. I still cannot believe the stock price is above $2.90 with the volume this low. It appears nearly every weak hand is out leaving only those in who will not settle for anything less than $4.00/share. The suspense is killing me. We'll see what happens.
Sorry...my last post sounded overly negative. I believe VRNG is an EXCELLENT long term play, and I firmly believe it will be a double-digit stock within 2 years. My time frame, however, is two months, and so I am very nervous that it will not perform within these narrow confines. If I had 24 months, though, or even 4-5 months, I would invest a ton of money in VRNG.
LOL! Rain, I can tell you're frustrated, and I'm with you on the frustration. I've about had it with VRNG, but I firmly believe there will be something down the pike in the next 2 months which will drive the share price back up to my break-even. However, in the last post you made to me you just violated the same "TOS" about which you charged me and the other guy with violating. How about we call it a night; happy trading and "cheers".
I just called and left a message with his secretary; she said he would return the call tomorrow as he is in meetings tonight. I listed his number again below. Maybe if we all call often enough they will tire of silence, preferring to inform us of the mundane via press conference or PR rather than through individual phone calls. Let the calling begin...(It ought to go without saying, of course, that politeness is as necessary as having a point to the call. Calling them up without poignant questions may more annoy than encourage them, leaving them frustrated with their investors, a situation which I would hope we'd like, collectively, to avoid):
Investor Relations Contact
Cliff Weinstein
Executive Vice President
Phone: 646.532.6777
cliff@vringo.com